Unwavering in the Quest to Eradicate COVID-19

EST. 2021

TechImmune is advancing the development of a next-generation, broad-spectrum COVID vaccine, designed to obviate the necessity for frequent updating and recurrent boosting that characterize existing vaccines. Our innovative strategy targets multiple antigens to elicit a comprehensive immune response, involving both antibody and T cell activation, in contrast to conventional vaccines that utilize the Spike protein to induce neutralizing antibodies. TechImmune's Coronavirus vaccine encompasses a more advanced approach to enhance long-lasting immunity and disrupt the current booster paradigm.


Gavin Herbert


Mr. Herbert has spent over 50 years in the pharmaceutical industry. He is the co-founder of Allergan Inc., CEO and Chairman of the Board for 30 years. Mr. Herbert served as Executive Vice President of SmithKline Beckman. He received his B.S. in Business, from the University of Southern California.

Jeffrey Ulmer, PhD

CEO and Board Member

Dr. Ulmer has >30 years of experience in Vaccines R&D and most recently served as the Global Head of External Research at Novartis and the Head of Preclinical R&D US at GSK Vaccines. Specialties: Biochemistry, Immunology and Cell Biology. Dr. Ulmer received his PhD from McGill University and post-doctoral fellowship at Yale University School of Medicine.

Richard Haugen

Rick Haugen
CFO and Board Member

Mr. Haugen was the CEO and President of a public firm, Amylin Pharmaceuticals. He spent 17 years with Allergan Inc. of Irvine culminating that career as Chief Operating Officer of the billion plus global company. He received his B.S. and MBA from the University of Southern California.

Lbachir BenMohamed, PhD

LBachir BenMohamed
Vice President and Board Member

In 2002, Dr. BenMohamed founded the Cellular & Molecular Immunology Laboratory at UC Irvine. He is the lead investigator for Techlmmune. He is a recipient of several United States National Institute of Health (NIH) grants. He completed his PhD in Immunology at the Pasteur Institute, Paris, France.

Dan Gil, PhD

Daniel Gil Headshot
COO and Board Member

Dr. Gil has had a 30+year career in Pharmaceutical R&D as VP of Research at Allergan. Dr. Gil has an undergraduate degree in Biology from Harvard University and a PhD in Pharmacology from University of Pennsylvania.

Dr. Trevor Jones CBE, PhD, DsC

Board Member

Former Head of Research for Burroughs Welcome, UK for over 20 years. Served as Head of British Pharmaceutical Association. He has been an advisor to the UK Government and G7 pandemic preparedness “100” days initiatives
to develop diagnostics, vaccines, and therapeutics for global use.

James Cavanaugh, PhD

James Cavanaugh PhD
Board Member

Dr. Cavanaugh is a Managing Director and Senior Advisor to HealthCare Venture LLC, a private equity and venture capital firm specializing in early stage biotechnology investments. He was previously President of SmithKline & French. He also served as President of Allergan International. Dr. Cavanaugh received his B.S. from Farleigh Dickinson University, M.A. and his Ph.D. from University of Iowa.

Our Mission

Develop and commercialize a next-generation broad-spectrum Covid vaccine to protect the public and economic health of individuals and societies globally.